A Phase 1 Study of Kappa and Mu Opioid Receptor Occupancy Associated With Repeated Dosing of LY24516302
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2015
Price : $35 *
At a glance
- Drugs Aticaprant (Primary)
- Indications Anxiety disorders
- Focus Therapeutic Use
- Acronyms FASTMAS
- 31 Aug 2018 Biomarkers information updated
- 26 May 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 26 May 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.